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Background: In Danish administrative registers, ejection fraction (EF) is not recorded,
which is a considerable limitation for correct subclassification of patients with heart failure
(HF). We hypothesized that a diagnosis of HF combined with the recorded prescription of
both renin-angiotensin system (RAS) inhibitors and beta- blockers (RASi+BB) within 120
days could identify patients with HF and reduced ejection fraction (EF ≤40%) (HFrEF).
Methods: On two sites, we identified all patients with a first-time registration of HF as
primary hospital discharge diagnosis (ICD-10: I50) between June 1, 2016, and May 31, 2018
in inpatient or outpatient settings. Patients were included if they survived the initial 120 days
after discharge. Reviewing patient records, we identified patients with HFrEF, based on EF ≤
40% and reported HF symptoms. We registered the use of RASi+BB at 120 days and
calculated sensitivity, specificity and predictive values.
Results: A total of 704 consecutive patients with a primary diagnosis of HF were included,
of whom 541 (77%) fulfilled the HFrEF criteria. Patients with HFrEF confirmed from patient
records were younger (median age 73 compared to 79 years) and less frequently women
(31% compared to 56%) compared to non-HFrEF patients. At baseline, 24 (4%) of HFrEF
patients were treated with RASi+BB compared to 22 (14%) of non-HFrEF patients. At 120
days, 460 (85%) of HFrEF patients received RASi+BB as compared to 25 (15%) of non-
HFrEF patients. This resulted in a positive predictive value of 95%, sensitivity of 85% and
specificity of 85%.
Conclusion: In Denmark, the ICD-10 HF diagnosis combined with recorded RASi+BB
treatment by 120 days after discharge has high positive predictive value and can accurately
be used to identify patients with HFrEF.
Keywords: heart failure, reduced ejection fraction, register data, validation
Introduction
Danish administrative registers have a high level of consistency and completeness
of data, and are, therefore, widely used for epidemiological studies. Due to a unique
personal identification number given to all Danish citizens at birth or immigration,
individuals can be identified in different registers and across different geographical
regions within Denmark.1,2 Identification of patients with heart failure (HF), based
on international classification of disease (ICD-10) codes has previously been
evaluated in the Danish registers documenting a relatively high positive predictive
value (PPV) ranging from 81% to 100% depending on which method was used for
validation.3–5 However, the ICD-10 system does not distinguish between HF with
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reduced (HFrEF) and preserved (HFpEF) ejection fraction
(EF), as the ICD-10 code for HF (I50) comprises both.
The network of Danish heart failure clinics ensures that
the majority of Danish citizens who are diagnosed with
HFrEF are offered consultations in a dedicated HF clinic
with a focus on uptitration of guideline-directed medical
therapy and patient education in self-care, usually over
a period of 4 to 6 months.6,7 Since renin-angiotensin
system inhibitors (RASi) and beta-blockers (BB) are
recommended for all patients with HFrEF, if tolerated,8
we hypothesized that patients with HFrEF who survived
the initial 120 days (~4 months) after receiving the diag-
nosis, could be identified based on the ICD-10 discharge
code and filled prescriptions of RASi+BB within that time
period.
Methods
This study was a part of a quality assurance project, with the
purpose of evaluating the proportion of patients with HF
alive after 120 days, who had initiated RASi and/or BB
within 90 and 120 days, respectively. In the National Patient
Register, we identified all patients who received a first-time
HF diagnosis (ICD-10: I50) as a primary discharge diag-
nosis on two sites, Gentofte University Hospital and Herlev
University Hospital, within a two-year period from June 1,
2016 through May 31, 2018. Patients who survived the
initial 120 days after the time of diagnosis were included.
Based on the review of patient records, patients were con-
sidered to have HFrEF if symptoms of HF were reported
and an EF ≤ 40% was documented in the chart. If several
echocardiograms had been performed, either during the
hospitalization or in the outpatient clinic, the first available
measurement of EF was used to define HFrEF status in
accordance with clinical practice. Symptoms of HF were
shortness of breath, reduced exercise tolerance, fatigue and/
or ankle swelling. Use of RASi (including angiotensin-
converting enzyme inhibitors [ACEi] and angiotensin
receptor blockers [ARB]) and BB was assessed at baseline
(treatment initiated before the time of diagnosis) and at 120
days after diagnosis.
Statistical Methods
Baseline characteristics were presented as absolute numbers
and proportions for categorical variables and medians and
inter-quartile ranges (IQR) for continuous variables.
Variables with missing data were presented as proportions
and IQR relative to the group of patients with available data.
Based on the ICD-10 discharge coding diagnosis for heart
failure (I50) and status of RASi+BB at 120 days, we calcu-
lated sensitivity, specificity and predictive values for HFrEF.
Ethical Considerations
Register studies and patient record review studies do not
require ethical approval in Denmark. The present quality
assurance project was approved by the hospital direction
(workzone number: 19,000,557). Patient data was anon-
ymized immediately, and individuals included in the ana-
lyses could not be identified at a later point.
Results
Study Population
A total of 704 patients had a first-time HF diagnosis
between June 1, 2016 and May 31, 2018 and were still
alive after 120 days. Of those, 541 (76.8%) had well-
described HFrEF. Less information was available for the
non-HFrEF group (n=163) and for 43 (26.4%) patients an
echocardiography had not been performed. Of the patients
with HFrEF, 503 (93.0%) attended the HF clinic compared
to only 21 (12.9%) of the non-HFrEF patients. Baseline
characteristics are listed in Table 1. Comorbidity data was
missing for 101 individuals – none of whom attended the
HF clinic.
Use of RASi and BB
At baseline, 24 (4.4%) patients with HFrEF and 22 (13.5%)
non-HFrEF patients were treated with RASi+BB. After 120
days, 460 (85.0%) patients with HFrEF and 25 (15.3%)
non-HFrEF patients were taking RASi+BB. For patients
with HFrEF who attended a HF clinic, 444 (88.3%) were
receiving RASi+BB therapy after 120 days, as illustrated in
Table 2. Identifying patients with HFrEF among patients
discharged with an I50 diagnosis, and based on treatment
with RASi+BB was associated with a PPV of 94.8% as
shown in Figure 1 and Table 3. This, however, came with
a sensitivity of 85.0%. An even higher PPVof 99.1% could
be obtained by selecting patients who were naïve to either
RASi or BB at the time of diagnosis. In this case, the
sensitivity was 80.1%.
Patients with HFrEF and Without RASi
and BB
According to patient records, reasons for not initiating
RASi and/or BB therapy in patients with HFrEF were
most often low blood pressure, low heart rate (BB), or
reduced renal function (RASi). However, comparing
Madelaire et al Dovepress
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baseline characteristics of patients with and without RASi
+BB at day 120 revealed no significant differences in pre-
sence on these three parameters. Patients without RASi+BB
were older with a median age of 79.7 (71.4, 87.0) years.
Patients Without Echocardiography
Patients without a documented echocardiography, n=43, were
classified as non-HFrEF. Among these patients, 6 (14%) were
takingRASI+BB at 120 days – the same 6 patients were treated
with RASi+BB at baseline.
Discussion
This study demonstrates that a population of patients with
HFrEF can be identified from the Danish registers based
on diagnosis and medical prescriptions with a PPVof 95%.
The ability to accurately identify patients with HFrEF is
important for the design and validity of future epidemio-
logical studies.
To our knowledge, this study is the first to evaluate the
identification of a specific HF subgroup in the Danish
administrative registers. The PPV of the HF diagnosis
has previously been evaluated with different approaches.
Table 1 Baseline Characteristics. Count/Median (Percentage, Inter-Quartile Range) [Data Available in % Individuals]
HFrEF (n=541) Non-HFrEF (n=163)
Female sex 169 (31.2) [100.0] 91 (55.8) [100.0]
Age 73.2 (63.9, 80.7) [100.0] 79.2 (71.8, 85.5) [100.0]
Hospitalization with HF symptoms 421 (77.8) [100.0] 83 (50.9) [97.5]
Attending heart failure clinic 503 (93.0) [100.0] 21 (12.9) [100.0]
Ischemic heart disease 167 (30.9) [100.0] 16 (25.8) [38.0]
Diabetes 81 (15.2) [100.0] 16 (25.8) [38.0]
Atrial fibrillation/flutter 224 (41.4) [100.0] 31 (50.0) [38.0]
Claudication 12 (2.2) [100.0] <3 (<4.8) [38.0]
Stroke 52 (9.6) [100.0] 9 (14.5) [38.0]
Chronic obstructive pulmonary disease 70 (12.9) [100.0] 12 (19.4) [38.0]
Medical therapy
Renin angiotensin system inhibitors 108 (20.0%) [100.0] 53 (32.5%) [100.0]
Beta-blocker 85 (15.7%) [100.0] 56 (34.4%) [100.0]
Renin angiotensin system inhibitors and beta-blocker 24 (4.4%) [100.0] 22 (13.5%) [100.0]
Clinical measurements
Left ventricular ejection fraction 30 (20, 37) [100.0] 55 (47, 60) [73.6]
Increased level of creatinine 99 (19.3%) [95.0] 10 (25.0%) [24.5]
Systolic blood pressure <100mmHg 18 (3.5%) [94.6] <3 (2.9%) [21.5]
Heart rate <60 beats per minute 56 (11.3%) [91.3] 3 (9.4%) [19.6]
NTproBNP 1510 (619, 3460) [79.7] 1375 (224, 3483) [13.5]
Abbreviations: HFrEF, heart failure with reduced ejection fraction; HF, heart failure.
Table 2 Frequency of RASi and Beta-Blocker Therapy After HF
Diagnosis
Baseline 120 Days
HFrEF (n=541)
RASi 108 (20.0) 496 (91.7)
Beta-blocker 85 (15.7) 492 (90.9)
RASi + beta-blocker 24 (4.4) 460 (85.0)
Neither 372 (68.8) 13 (2.4)
HFrEF in HF clinic (n=503)
RASi 94 (18.7) 473 (94.0)
Beta-blocker 69 (13.7) 469 (93.2)
RASi + beta-blocker 19 (3.8) 444 (88.3)
Neither 359 (71.4) 5 (1.2)
Non-HFrEF (n=163)
RASi 53 (32.5) 59 (36.2)
Beta-blocker 56 (34.4) 63 (38.7)
RASi + beta-blocker 22 (13.5) 25 (15.3)
Neither 76 (46.6) 66 (40.5)
Non-HFrEF in HF clinic (n=21)
RASi 8 (38.1) 9 (42.9)
Beta-blocker <3 (<7.0) 3 (7.0)
RASi + beta-blocker <3 (<7.0) <3 (<7.0)
Neither 11 (52.4) 10 (47.6)
Dovepress Madelaire et al
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In a study using discharge summaries to verify the diag-
nosis, the PPV was found to be 100% for 50 patients
reviewed.5 This method solely relied on the opinion of
the discharging physician and it is unknown whether diag-
nostic tests were performed. This is a valuable method to
ensure that the National Patients Register is reflecting the
diagnoses given at discharge, but it is less valuable for
determining whether the diagnostic criteria were met in the
clinical situation. Therefore, important additional data
were obtained, when 3201 hospitalized patients were eval-
uated with a clinical examination and echocardiography in
another previous study. In this study, the PPV was found to
be 81%, as 30 patients out of 156 with a registered diag-
nosis, did not have HF according to the European Society
of Cardiology criteria.3 Moreover, this study revealed a
low sensitivity of 29% (39% for HFrEF) among all
patients hospitalized. The study included patients admitted
to any department and did not consider prior diagnoses,
which may explain the low sensitivity, as the HF diagnosis
patient with well-known and well-treated HF may not have
been recorded if the patient was admitted for non-cardio-
vascular comorbidity. The sensitivity of the register-based
approach documented in the present study is not compar-
able to the study by Kumler, as the current study is derived
from a population with registered HF. Consequently, the
results of the current study reflect the proportion of true
HFrEF among patients with a HF diagnosis identified
using our definition. The main purpose, however, was to
estimate the PPV of HFrEF, and we found that it was
surprisingly high even when only using the diagnosis
(541/704) = 77%. When adding RASi+BB use to the
definition, 219 patients were redefined as non-HFrEF, of
whom, at least 81 had HFrEF. In the group of non-HFrEF
patients, the description of symptoms of HF in the medical
records was less detailed, and NTproBNP was only mea-
sured in a few patients. Hence, it was, therefore, difficult
to determine the proportion of true HFpEF. Due to a lack
of echocardiography for some patients, we cannot rule out
that they had HFrEF. If this were the case, for all these
Figure 1 Left side: Patients identified as HFrEF (blue) and non-HFrEF (red) plotted with age and EF. Patients without information on EF (green) plotted along the age-axis.
Right side: Sensitivity, specificity and positive predictive value of confirmed HFrEF by using diagnosis code and RASi+BB at 120 days.
Abbreviations: EF, ejection fraction; HFrEF, heart failure with reduced ejection fraction; RASi, renin-angiotensin-system inhibitor; BB, beta-blocker.
Table 3 Sensitivity, Specificity and Predictive Values of
Confirmed HFrEF by Using Diagnosis Code and RASi+BB at
120 Days
Non-HFrEF HFrEF Total
Not RASi and beta-blocker 138 81 219
RASi and beta-blocker 25 460 485
Total 163 541 704
Notes: Sensitivity, 460/541 = 85.0%. Specificity, 138/163 = 84.7%. Positive predic-
tive value: 460/485 = 94.8%. Negative predictive value: 138/219 = 63.0%.
Madelaire et al Dovepress
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patients it would slightly increase the PPV to 96%, while
reducing the sensitivity to 80%.
The proportion of HFpEF was low, even if all patients
categorized as non-HFrEF had true HFpEF. This propor-
tion has varied in the literature depending on definition,
method and clinical settings. From the European Society
of Cardiology HF Long-Term Registry, it has been
reported that a third of the patients with chronic HF had
an EF >40%.9 In the hospital, HFpEF may be underre-
ported in the presence of comorbidity, and it is unknown
how many patients are merely treated symptomatically
with diuretic therapy without having a registered HF diag-
nosis. In a recent Danish study examining patients with
risk factors for HF but without known HF, 37% had an
abnormal echocardiography but no symptoms of HF (stage
B HF), while 18% had abnormal echocardiography and
symptoms of HF (stage C HF).10 Among those with unrec-
ognized HF (stage C) 94% had an EF>40%, which sup-
ports the hypothesis of HFpEF being underdiagnosed.
Further, even recognized HFpEF may have low registra-
tion rates in Denmark due to our public tax-paid health
care system, where registration of a diagnosis is not asso-
ciated with the same financial or competitive benefits for
the hospitals as in other countries. This does not affect the
validity of the data presented, but it may affect the general-
izability of the proposed method to other countries; the
PPV will be lower in populations with a higher proportion
of HFpEF. Therefore, this method should be tested in other
cohorts before being applied in settings different from the
Danish.
A considerable part of the cohort did not receive RASi
+BB by 120 days. The reported rationale of avoiding/
postponing initiation of RASi was often a high level of
creatinine, while BB was often avoided/postponed due to
low blood pressure or low heart rate. However, we
observed no significant difference in the frequency of
low blood pressure, heart rate, or high level of creatinine
at baseline between patients with and without RASi+BB at
day 120. It is likely that the treatment decision is partly
based on the patients’ clinical appearance, and parameters
such as a low cardiac output state may indicate full up-
titration of RASi before initiation of (and therefore post-
poning) BB. Another explanation could be that patients
who experienced an early readmission had a delay in
otherwise planned interventions and up-titration of medi-
cal therapy. However, early readmission rates are low in
Denmark, so this should only apply to a minority of the
patients.11 Noticeably, only 2% of the patients with HFrEF
initiated neither RASi nor BB. Further, it is unknown how
many of these patients initiated RASi+BB at a later point
after 120 days.
Strengths and Limitations
The Danish health care system is highly homogenous in
terms of diagnostic approaches, treatment strategies and
quality of care, which is a major strength for a study as the
present, relying on nationwide generalizability. The two
hospitals included were both university hospitals, but
represented both invasive and non-invasive cardiology
departments.
Defining HFrEF in the Danish registers using the
I50 code and post-discharge initiation of RASi+BB within
a certain period inherently results in the exclusion of
patients dying within this period, which introduces selec-
tion bias towards the younger and less frail patients.
Unfortunately, we did not have data regarding these
excluded patients; however, in previous work on data
from the nationwide registers, 20% of 172,580 patients
diagnosed with HF from 2000 to 2012 died within
120 days – including those who died during the initial
hospitalization.12 The distribution of early death between
patients with and without HFrEF is unknown. Further, the
present analyses showed a loss of 15% of the patients with
HFrEF surviving the initial 120 days, using the proposed
method. These patients were older than the included
patients were and, likely, more frail. This should be kept
in mind when applying the method in future epidemiolo-
gical research, but it may be less important for studies
concerning patients with chronic HF.
We acknowledge that estimating EF is susceptible to
inter- and intra-observer variability and patients with an
EF close to 40% could be misclassified. However, this
reflects the daily clinical practice and is not considered
a limitation for the purpose of this study.
Conclusions
In Danish administrative registers, the combination of a
HF and initiation of RASi as well as BB by 120 days after
diagnosis defines HFrEF with a PPV of 95%. Despite a
sensitivity of 85%, using this method for register studies is
reasonable.
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